Allstate Protection Plans Enhances Its Portfolio of Offerings for the Mobile Industry with Kingfisher Acquisition
14.10.2024 14:00:00 CEST | Business Wire | Press release
Allstate Protection Plans, a division of Allstate Corporation (NYSE: ALL), has acquired Kingfisher, a privately held company that optimizes the lifecycle of smart devices (repair, replace, trade-in, upgrade) to enhance offerings for the mobile industry and their customers. This strategic acquisition strengthens Allstate Protection Plans’ ability to provide innovative solutions that help consumers get the most out of their devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241014219868/en/

(Graphic: Business Wire)
Founded in 2016, Kingfisher has been a pioneer of the mobile circular economy, offering a suite of products that help mobile carriers, manufacturers, and retailers meet the increasing consumer demand for flexible ownership and protection solutions that reduce their environmental impact. The acquisition brings Kingfisher’s team of mobile experts to an Allstate team that has disrupted the device protection industry over the past two decades and serves over 150 million customers worldwide.
“Allstate Protection Plans partners with some of the world’s leading mobile carriers, including Telenor Group, Softbank, Three, and T-Mobile, and the mobile industry remains a key area of growth for us globally,” said Karl Wiley, Global President and CEO of Allstate Protection Plans. “We are thrilled to welcome the Kingfisher team to Allstate. By bringing this world-class team of experts onboard, we gain a significant competitive advantage over traditional companies in the wireless industry, further enhancing our ability to meet the evolving needs of carriers and consumers alike.”
"We entered the market with the belief that carriers and consumers deserve a better, more flexible mobile experience," said Georgiann Reigle, Co-Founder and CEO of Kingfisher. "With the global reach, resources, and financial strength of Allstate, we are now positioned to drive the efficient circulation of both new and second-life devices to potentially billions of users, significantly reducing the environmental impact of mobile device usage worldwide.”
For more information, visit www.allstateprotectionplans.com.
About Allstate Protection Plans
For nearly two decades, Allstate Protection Plans has transformed the extended warranty industry with service innovation and an obsessive focus on the customer experience. Today, Allstate Protection Plans is trusted by over 150 million customers as well as leading mobile operators and retailers in North America, Europe, Japan, and Australia. Allstate Protection Plans are available for mobile devices, electronics, appliances, furniture, and more than 20 other product categories. Allstate Protection Plans is a wholly owned subsidiary of The Allstate Corporation.
About Kingfisher
Kingfisher is a next-gen mobile experience company, totally re-engineering the mobile experience economy. People-first by design, we’re obsessed with optimizing the lifecycle of connected devices, developing end-to-end experience solutions, designed to transform the mobile experience economy for carriers, their customers, and the planet. Through our ingenious solutions, we extend the lifespan of connected devices by powering the efficient circulation of new and second-life devices within the global value chain, creating circular transformation at scale. Find out more on how we’re transforming the industry at: www.kingfisher-mx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241014219868/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom